Leventer-Roberts Maya, Hammerman Ariel, Brufman Ilan, Hoshen Moshe, Braun Marius, Ashur Yaffa, Lieberman Nicky, Balicer Ran
Clalit Research Institute, Tel Aviv, Israel.
Icahn School of Medicine at Mount Sinai, New York, New York, United States of America.
PLoS One. 2017 Jul 7;12(7):e0176858. doi: 10.1371/journal.pone.0176858. eCollection 2017.
Direct acting antivirals for hepatitis C virus have shown dramatic results in clinical trials. However, their effectiveness has yet to be demonstrated within observational cohorts which lack exclusion criteria found in randomized control trials.
To determine the effectiveness of dasabuvir/ombitasvir/paritaprevir/ritonavir in achieving sustained virological response.
Retrospective observational cohort study of all Clalit Health Services members with hepatitis C virus genotype 1 who were dispensed dasabuvir/ombitasvir/paritaprevir/ritonavir from January 1, 2015 to-November 31, 2015.
There were 564 participants during the study period. The average age was 61.9 years, 52.0% were male, and 61.5% were born Eastern/Central Europe or Central Asia. The prevalence of diabetes was 31.7% and 70.3% were overweight/obese. Cirrhosis was present in 41.0% of participants, of whom 52.8% had stage 4 fibrosis. Of the cohort, 416 (74.8%) had follow-up viral load testing at 10 or more weeks after the end of treatment. We report a sustained virological response of 98.8% among those tested.
Treatment with dasabuvir/ombitasvir/paritaprevir/ritonavir demonstrated a near universal effectiveness in achieving a sustained virological response among HCV patients in a large cohort.
丙型肝炎病毒直接作用抗病毒药物在临床试验中已显示出显著效果。然而,在缺乏随机对照试验中所设排除标准的观察性队列中,其有效性尚未得到证实。
确定达沙布韦/奥比他韦/帕利瑞韦/利托那韦实现持续病毒学应答的有效性。
对2015年1月1日至2015年11月31日期间所有接受达沙布韦/奥比他韦/帕利瑞韦/利托那韦治疗的Clalit健康服务机构中丙型肝炎病毒1型感染者进行回顾性观察性队列研究。
研究期间有564名参与者。平均年龄为61.9岁,52.0%为男性,61.5%出生于东欧/中欧或中亚。糖尿病患病率为31.7%,70.3%超重/肥胖。41.0%的参与者存在肝硬化,其中52.8%有4期纤维化。在该队列中,416名(74.8%)在治疗结束后10周或更长时间进行了随访病毒载量检测。我们报告在接受检测者中持续病毒学应答率为98.8%。
在一个大型队列中,使用达沙布韦/奥比他韦/帕利瑞韦/利托那韦治疗在丙型肝炎患者中显示出近乎普遍的实现持续病毒学应答的有效性。